Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.

Area of Science:

• Hematology
• Oncology
• Genomics

Background:

• Plasmablastic lymphoma (PBL) is a rare, aggressive non-Hodgkin lymphoma.
• PBL is strongly associated with immunosuppression and has a poor clinical prognosis.
• Its molecular pathogenesis remains poorly understood, despite characteristic plasmacytic differentiation and frequent Epstein-Barr virus (EBV) association.

Purpose of the Study:

• To conduct a comprehensive integrated genomic analysis of a large cohort of primary PBL samples.
• To identify key molecular alterations driving PBL pathogenesis.
• To uncover potential therapeutic targets for improving PBL patient outcomes.

Main Methods:

• Whole exome sequencing (WES) and genome-wide copy number analysis were performed on 96 primary PBL samples.
• Integrated genomic data were analyzed to identify recurrent genetic alterations.
• Functional impact of identified alterations was assessed using an unbiased shRNA screen in a PBL model.

Main Results:

• Identified frequent alterations activating the RAS-RAF, JAK-STAT, and NOTCH signaling pathways.
• Discovered high-level amplifications in MCL1 and IRF4 in a significant proportion of PBL cases.
• Validated the functional relevance of these pathways through shRNA screening.

Conclusions:

• The study highlights recurrent genomic alterations in key signaling pathways in PBL.
• IRF4 and JAK-STAT pathways emerge as promising molecular targets for novel therapeutic strategies.
• Targeting these pathways may offer a route to improve the poor outcomes associated with Plasmablastic Lymphoma.